Retension Pharmaceuticals Seen as Undervalued Ahead of Key Blood Pressure Trial, Oppenheimer Says

12:19 PM EST, 11/03/2026 (MT Newswires) -- Retension Pharmaceuticals (RTSN) could see substantial upside if an ongoing mid-stage study of its lead blood pressure treatment produces positive results, Oppenheimer said Tuesday in a report initiating coverage of the stock. Results from the company's phase 2b trial of RTN-001, expected in H1 2027, could support further development of the drug and highlight its advantages over existing treatments, Oppenheimer said. Oppenheimer said three earlier phase 2 studies showed meaningful reductions in blood pressure among patients whose hypertension remained difficult to control, while also demonstrating a favorable safety profile. The ongoing study is evaluating a modified-release version of the drug that may improve its effectiveness, the report said. Oppenheimer estimates that about 40 million US patients have uncontrolled or treatment-resistant hypertension, representing a significant commercial opportunity for Retension. Physician survey results support the potential use of RTN-001 in patients with chronic kidney disease, a common condition among people with hypertension, the report said. Oppenheimer has an outperform rating on Retension stock with a $50 price target. Price: 12.09, Change: +0.79, Percent Change: +6.99